More than two-thirds (68%) of the respondents to the survey expressed confidence that the COVID-19 is "behind us." An overwhelming majority (80%), though, indicated that annual COVID-19 vaccination will be needed for the foreseeable future.
Most every measure of the COVID-19 pandemic is trending downward, according to the Centers for Disease Control and Prevention (CDC). The CDC tracker this morning shows 1,052 deaths on weekly basis and an average of 1,511 daily hospitalization admissions.
Although the 2023 Annual Managed Healthcare Executive Pharmacy Survey was conducted Feb. 14-28, just over two-thirds (68%) of the approximately 300 respondents indicated then they were confident or very confident that the COVID-19 “was behind us.” Just 9% indicated that they were not confident that was not so.
Whether the methods used to count COVID-19 deaths are undercounting or overcounting the deaths from the disease has become an active controversy. In her column in the Washington Post, Leana Wen, M.D., M.Sc., a professor George Washington’s Milken Institute School of Public Health has argued that deaths being overcounted. Others have argued that the problem is undercounting.
Respondents to the Pharmacy Survey were solidly in the overcounting camp, with two-thirds (67%) indicated that they believed that deaths from COVID-19 were being overcounted. Nonetheless, a large majority (80%) said they believe annual COVID-19 vaccines will be needed for the foreseeable future.
The respondents were spread fairly evenly across the various sectors of the U.S. healthcare industry, with 20% self-identifying as working for hospitals, 22% for physician practices, 19% for pharmacy benefit managers, 16% for payer organizations, 13% for drug and device manufacturers and the rest in a variety of sectors.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Early Genetic Testing Avoids Treatment Delays for Patients with Friedreich Ataxia
September 18th 2024Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen